Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Teva Pharmaceutical Industries



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.7%. By the end of trading, Teva Pharmaceutical Industries rose 41 cents (1%) to $40.12 on average volume. Throughout the day, 2.6 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 2.9 million shares. The stock ranged in a price between $39.77-$40.19 after having opened the day at $39.91 as compared to the previous trading day's close of $39.71. Other companies within the Drugs industry that increased today were:




), up 24.5%,

AcelRx Pharmaceuticals



), up 19.8%,




), up 19.1%, and

Galectin Therapeutics



), up 18.3%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $34.15 billion and is part of the health care sector. The company has a P/E ratio of 10.6, below the S&P 500 P/E ratio of 17.7. Shares are down 2.5% year to date as of the close of trading on Friday. Currently there are 17 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and eight rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share.

On the negative front,

Palatin Technologies



), down 13.2%,

Oxygen Biotherapeutics



), down 11.1%,

IntelliPharmaCeutics International



), down 8.3%, and

Alexza Pharmaceuticals



), down 8.3%, were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!